1. Volume 2, Issue 6, Pages 563-571 (June 2015)
Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide 
Yang Shen, Ya-Kai Fu, Yong-Mei Zhu, Yin-Jun Lou, Zhao-Hui Gu, Jing-Yi Shi, Bing Chen, Chao Chen, Hong-Hu Zhu, Jiong Hu, Wei-Li Zhao, Jian-Qing Mi, Li Chen, Hong-Ming Zhu, Zhi-Xiang Shen, Jie Jin, Zhen-Yi Wang, Jun-Min Li, Zhu Chen, Sai-Juan Chen 
EBioMedicine 
Volume 2, Issue 6, Pages (June 2015)
DOI: /j.ebiom
Copyright © 2015 The Authors Terms and Conditions

2. Fig. 1
Correlation between gene mutations and clinical risk groups. High-risk patients contained more mutations additional to PML–RARα (50.4%, 66/131) as compared with intermediate- (25.0%, 62/248, P<0.001) and low-risk (23.1%, 36/156, P<0.001) groups.
EBioMedicine 2015 2, DOI: ( /j.ebiom )
Copyright © 2015 The Authors Terms and Conditions

3. Fig. 2
Kaplan–Meier curves for overall survival (OS) and disease-free survival (DFS) according to Sanz's risk stratification in univariate analysis. (A, B) OS and DFS of different risk groups in training group. (C, D) OS and DFS of different risk groups in validation group.
EBioMedicine 2015 2, DOI: ( /j.ebiom )
Copyright © 2015 The Authors Terms and Conditions

4. Fig. 3
Kaplan–Meier curves for overall survival (OS) and disease free survival (DFS) according to EMG mutational status in univariate analysis. (A, B) OS and DFS of patients with EMG mutations in training group. (C, D) OS and DFS of patients with EMG mutations in validation group.
EBioMedicine 2015 2, DOI: ( /j.ebiom )
Copyright © 2015 The Authors Terms and Conditions

5. Fig. 4
Kaplan–Meier curves for overall survival (OS) and disease free survival (DFS) according to FLT3 mutational status in univariate analysis. (A, B) OS and DFS of patients with FLT3 mutations in training group. (C, D) OS and DFS of patients with FLT3 mutations in validation group.
EBioMedicine 2015 2, DOI: ( /j.ebiom )
Copyright © 2015 The Authors Terms and Conditions